Reversal

American College of Lifestyle Medicine announces Type 2 Diabetes Remission Certificate for physicians and health professionals completing prerequisite CME/CE training

Retrieved on: 
Wednesday, June 21, 2023
Physician, Sleep, Insulin resistance, Knowledge, ACLM, Literature, Type 2 diabetes, ST, Insulin, American College, Patient, Reversal, Pharmaceutical industry

ST. LOUIS, Mo., June 21, 2023 /PRNewswire-PRWeb/ -- The American College of Lifestyle Medicine (ACLM) has announced a new Type 2 Diabetes Remission Certificate to be awarded to physicians and eligible health professionals that signifies specialized knowledge and competency in evidence-based lifestyle medicine to support the treatment, remission, and prevention of type 2 diabetes and reversal of insulin resistance.

Key Points: 
  • Those who are eligible and complete the 18-hour course will receive a certificate signifying specialized knowledge and competency in evidence-based lifestyle medicine to support the treatment, remission, and prevention of type 2 diabetes and insulin resistance.
  • ST. LOUIS, Mo., June 21, 2023 /PRNewswire-PRWeb/ -- The American College of Lifestyle Medicine (ACLM) has announced a new Type 2 Diabetes Remission Certificate to be awarded to physicians and eligible health professionals that signifies specialized knowledge and competency in evidence-based lifestyle medicine to support the treatment, remission, and prevention of type 2 diabetes and reversal of insulin resistance.
  • Physicians and eligible health professionals earn the certificate by completing "Remission of Type 2 Diabetes and Reversal of Insulin Resistance with Lifestyle Medicine," an 18-hour continuing medical education/continuing education (CME/CE) course created by experts and researchers with proven success treating patients with type 2 diabetes using lifestyle medicine.
  • The course discusses the role of nutrition, physical activity, sleep and other essential factors, and reviews the current literature around medication deprescribing for type 2 diabetes remission and reversal of insulin resistance, as well as definitions and success rates.

Baudax Bio Reports First Quarter Financial Results and Provides Business Update

Retrieved on: 
Friday, May 12, 2023
Transfer, Purchasing, IV, Anesthesiology, New Drug Application, Plasma protein binding, DRS, See, Associate, Development, Agent, Patient, National Association, Three Months, PSA, Amendment, Wilmington Trust, Credit agreements in South Africa, EMG, Pharmacokinetics, ATLA, Teenage Mutant Ninja Turtles (2003 TV series, season 6), IND, The Transfer Agreement, Safety, Volunteering, Bromide, NMB, University, Clinical research, Research, Good, National Railway Company of Belgium, Reversal, Series, Intubation, Perioperative medicine, Pharmaceutical industry, Vaccine, Birth control, Security (finance), Cryptocurrency, Asset, Anesthesia, Credit, Alkermes, Creditor

MALVERN, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the quarter ended March 31, 2023, and provided a business update.

Key Points: 
  • MALVERN, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the quarter ended March 31, 2023, and provided a business update.
  • Baudax Bio expects to complete nonclinical studies and manufacturing data required to support the IND for BX3000 in late summer of 2023.
  • Financial Results for the Three Months Ended March 31, 2023
    As of March 31, 2023, Baudax Bio had cash and cash equivalents of $3.8 million.
  • Baudax Bio reported net loss from continuing operations of $(7.4) million, or $(3.19) per share, for the three months ended March 31, 2023.

Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs

Retrieved on: 
Tuesday, April 25, 2023
Interim, Partnership, Reversal, Food and Drug Administration, Presbyopia, NDA, DR, DRSS, RM, LDP, OCUP, PDUFA date, PDUFA, Diabetic retinopathy, MIRA, FDA, Food, Safety, Pharmaceutical industry, Viatris

FARMINGTON HILLS, Mich., April 25, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that the Company will release its first quarter 2023 financial results on Monday, May 15, 2023. The Company also provided a corporate update, reiterating its previous guidance on its clinical programs.

Key Points: 
  • The Company also provided a corporate update, reiterating its previous guidance on its clinical programs.
  • “All development program timelines remain unchanged from previous guidance and the Ocuphire team is committed to executing on our near-term priorities.
  • 2023 is a pivotal year for Ocuphire with multiple potential late-stage clinical, regulatory, and product approval catalysts across the Nyxol and APX3330 programs,” said Rick Rodgers, Interim CEO and President of Ocuphire.
  • The financial elements of the agreement have strengthened Ocuphire’s balance sheet and provides additional capital to help advance APX3330 .

Study: Testosterone Pellet Therapy Significantly Improves Bone Density in Male Patient Case Report

Retrieved on: 
Monday, March 27, 2023
Health, Other Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Health Promotion International, Workgroup, Testosterone, Male, Molina Healthcare, Habit, Osteoporosis, Reversal, Skiing, Hip, Quality of life, Bone density, Spine, Woman, DIM, Sleep apnea, Snow, Bone, Drinking, Ageing, Patient, Risk, Water, Fracture, Diagnosis, DEXA, Smoking, International Society, Disease, Dentistry, Dietary supplement, Medical device, Biot–Savart law

The results of “Subcutaneous Testosterone Pellet Therapy for Reversal of Male Osteoporosis: A Review and Case Report” were published in the peer-reviewed medical journal “The Aging Male,” the official journal of the International Society for the Study of the Aging Male.

Key Points: 
  • The results of “Subcutaneous Testosterone Pellet Therapy for Reversal of Male Osteoporosis: A Review and Case Report” were published in the peer-reviewed medical journal “The Aging Male,” the official journal of the International Society for the Study of the Aging Male.
  • After three months the patient’s testosterone level was up to 943 ng/dL, and after one year of continued testosterone therapy the patient’s repeated DEXA scan showed an improvement to his composite bone density, substantially normalizing his total hip bone density.
  • The patient also returned to performing triathlons one year after the beginning of testosterone pellet therapy.
  • Low testosterone in men is associated with a clear decrease in bone mineral density, which in turn is associated with a significant increase in bone fractures.

Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 23, 2023
Clinical trial, Pain management, Marketing, Safety, Depreciation, Volunteering, Research, Hospital, IND, GAAP, Bromide, Three Months, Travel, Pharmacokinetics, FDA, NMB, Patient, Series, A-3, Intubation, Completion, Reversal, Phase, Good, IV, Pharmaceutical industry, Birth control, Cryptocurrency

MALVERN, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the fourth quarter and year ended December 31, 2022, updated the status of the neuromuscular blocking (NMB) agent development program, and provided an overview of other corporate and financial developments.

Key Points: 
  • Results for a planned interim analysis of the Phase II trial for BX1000 were announced in January 2023.
  • As a result, Baudax Bio has formally discontinued the commercialization of ANJESO and the product is currently on hold due to these business conditions.
  • Financial Results for the Three Months Ended December 31, 2022
    As of December 31, 2022, Baudax had cash and cash equivalents of $5.3 million.
  • Non-GAAP financial measures should be considered in addition to, but not as a substitute for, reported GAAP results.

Reversed TV series teams with Dr Robert Kiltz, MD and other well-known doctors on a new season featuring the Carnivore Diet

Retrieved on: 
Friday, December 30, 2022
Organization, Diet, Fasting, Talk, Summer, Name, Today (American TV program), Bone marrow, Reversal, Health, Phil Glew, Amazon, Degenerative disease, Fertility, Blog, Life, OTT, Diabetes, Emmy Awards, Multimedia, Eating, Season, CNN, Salmon, Butter, Type 2 diabetes, Pharmaceutical industry, Feed manufacturing, Carnivore, MD

The second season focused on using the ketogenic diet and intermittent fasting to help change the lives of its guests.

Key Points: 
  • The second season focused on using the ketogenic diet and intermittent fasting to help change the lives of its guests.
  • Reversed season 3 will use the Carnivore diet to improve the health of those living with different conditions.
  • Dr. Kiltz is a passionate advocate of the carnivore diet for fertility and many other aspects of human health.
  • He launched season one of Reversed in 2017, with a vision and passion to help people live better lives.

Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Tuesday, November 8, 2022
BX, IND, Asset, Travel, Meloxicam, Lesbian flag, Company, Program, Security (finance), Director, Hospital, IV, Marketing, United States Patent and Trademark Office, Patent, Board, News, U.S. Securities and Exchange Commission, Pharmacokinetics, Intubation, Research, GAAP, Patient, CEO, COVID-19, Vomiting, Analgesic, Omicron, Constipation, Depreciation, NSAID, Phase, Nausea, Volunteering, FDA, GLOBE, Nasdaq, Intellectual property, National Railway Company of Belgium, ASC, Technology, Reversal, NASDAQ, Safety, Hypoventilation, Pain, NMB, Therapy, Orange Book, Pharmaceutical industry, Video game, Birth control, Risk management, Reinsurance

MALVERN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the three and nine months ended September 30, 2022, updated the status of the neuromuscular blocking (NMB) agent development program, provided key metrics around the ongoing commercialization of ANJESO (meloxicam) injection, and provided an overview of other corporate and financial developments.

Key Points: 
  • Baudax Bio expects to complete nonclinical studies and manufacturing data required to support the IND for BX3000 in the first half of 2023.
  • In August 2022, Baudax Bio announced that the United States Patent and Trademark Office (USPTO) had provided a Notice of Allowance for patent application No.
  • As of September 30, 2022, Baudax Bio had cash and cash equivalents of $5.6 million.
  • These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.

Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update

Retrieved on: 
Friday, August 12, 2022
OCUP, U.S. Securities and Exchange Commission, Risk, CEO, GLOBE, SEC, Clinical trial, Patent, Board, Reversal, Security (finance), NVD, Method, Patient, ASRS, Board of directors, Diabetes, OD, NDA, Inflammation, Industry, Phentolamine, Private Securities Litigation Reform Act, APX, Pilocarpine, DNA, Diabetic retinopathy, Safety, Doctor of Philosophy, Nasdaq, CMC, Ageing, Visual acuity, DME, Use, Frontiers, COVID-19, LDP, Maintenance, Expected, NF-κB, FDA, Observation, Chronic pain, Society, Light, Review, Company, NASDAQ, Research, MBA, Retina, Pharmaceutical industry, Medical device, Tutoring, Online gambling, MD, Presbyopia, Mydriasis, RM, DR

FARMINGTON HILLS, Mich., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Key Points: 
  • We look forward to reporting top-line results in the second half of this year from the Phase 2b trial of APX3330 in diabetic retinopathy (DR).
  • We are well positioned to deliver on our upcoming late-stage clinical and regulatory milestones through the second half of 2022.
  • Second Quarter Ended June 30, 2022 Financial Highlights
    As of June 30, 2022, Ocuphire had cash and cash equivalents of approximately $17.0 million.
  • Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Thursday, August 11, 2022
FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Vial, Vomiting, Nausea, Intellectual property, U.S. Securities and Exchange Commission, CEO, Omicron, Trial of the century, GLOBE, Analgesic, IV, Technology, ASC, Paralysis, NMB, IND, Hospital, Patent, Reversal, Security (finance), Nasdaq, Pain, Marketing, Patient, Hypoventilation, NSAID, COVID-19, Company, Depreciation, Program, Therapy, Meloxicam, Safety, NASDAQ, GAAP, Research, Time, National Railway Company of Belgium, Food, Pharmacokinetics, Constipation, Pharmaceutical industry, Cryptocurrency

MALVERN, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today reported financial results for the three and six months ended June 30, 2022, provided key metrics around the ongoing commercialization of ANJESO (meloxicam) injection, updated status of the neuromuscular blocking (NMB) agent development program, and provided an overview of other corporate and financial developments.

Key Points: 
  • ANJESO continued its solid sales performance during the second quarter of 2022 with 49% growth year-over-year, said Gerri Henwood, President and CEO of Baudax Bio.
  • For the second quarter of 2022, ANJESO achieved net product revenue of $0.3 million, reflecting 49% growth year-over-year.
  • In terms of site of care usage of ANJESO, there was a 12% increase in vials sold to hospitals in the second quarter of 2022 compared to the first quarter of 2022.
  • In the second quarter of 2022 the re-order rate from existing accounts was 72%.

Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances

Retrieved on: 
Thursday, May 19, 2022
MBA, Severe cognitive impairment, Nasdaq, LYNX, Patient, Reversal, Visual acuity, Light, FDA, Safety, NDA, Vision, Diabetes, OCUP, Cornea, Pupil, GLOBE, CEO, NVD, Pharmaceutical industry, Telescopic sight, Presbyopia, Mydriasis

FARMINGTON HILLS, Mich., May 19, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced positive topline results from the LYNX-1 Phase 3 pivotal clinical trial investigating its product candidate Nyxol® for night (or dim light) vision disturbances (NVD). Across 12 US clinical trials with approximately 1100 subjects, over 650 subjects have now been exposed to Nyxol.

Key Points: 
  • LYNX-1 represents our sixth consecutive positive data readout for Nyxol in several indications and is a critical milestone towards future product registration.
  • Importantly, the LYNX-1 trial results provide additional support for the safety and vision improvement benefits of Nyxol in RM and presbyopia in dim light conditions.
  • Ocuphire also reported positive topline data from a Phase 2 trial of Nyxol for treatment of presbyopia, both Nyxol as a single agent and Nyxol with low dose pilocarpine (LDP) 0.4% as adjunctive therapy.
  • The Company recently reported positive topline results from LYNX-1 Phase 3 trial of Nyxol for NVD.